INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
University of Queensland
Brisbane, AustraliaPublicacións en colaboración con investigadores/as de University of Queensland (30)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone
Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536
-
Reduction in size of the calcifying phytoplankton Calcidiscus leptoporus to environmental changes between the Holocene and modern Subantarctic Southern Ocean
Frontiers in Marine Science, Vol. 10
2022
-
Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs
Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328
-
IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385
-
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Blood Advances
2021
-
1q21.1 distal copy number variants are associated with cerebral and cognitive alterations in humans
Translational psychiatry, Vol. 11, Núm. 1, pp. 182
-
A facility and community-based assessment of scabies in rural Malawi
PLoS neglected tropical diseases, Vol. 15, Núm. 6, pp. e0009386
-
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
BMC Infectious Diseases, Vol. 21, Núm. 1
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19
New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802
2020
-
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study
Blood, Vol. 136, Núm. 18, pp. 2038-2050
-
Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region with Cortical and Subcortical Morphology and Cognition
JAMA Psychiatry, Vol. 77, Núm. 4, pp. 420-430
-
Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis
Journal of Clinical Oncology, Vol. 38, Núm. 28, pp. 3252-3260
-
Characteristics of Early Paget's Disease in SQSTM1 Mutation Carriers: Baseline Analysis of the ZiPP Study Cohort
Journal of Bone and Mineral Research, Vol. 35, Núm. 7, pp. 1246-1252
-
Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia
Molecular Psychiatry, Vol. 25, Núm. 3, pp. 584-602
-
Limited variability in the phytoplankton Emiliania huxleyi since the pre-industrial era in the Subantarctic Southern Ocean
Anthropocene, Vol. 31
-
The interRAI Suite of Mental Health Assessment Instruments: An Integrated System for the Continuum of Care
Frontiers in Psychiatry, Vol. 10
2019
-
Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations
Clinical Pharmacokinetics, Vol. 58, Núm. 6, pp. 767-780
-
Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone
BMJ Open, Vol. 9, Núm. 9